158 related articles for article (PubMed ID: 15061206)
21. Thalidomide in the treatment of relapsed multiple myeloma.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR
Mayo Clin Proc; 2000 Sep; 75(9):897-901. PubMed ID: 10994824
[TBL] [Abstract][Full Text] [Related]
22. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
23. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
Yakoub-Agha I; Attal M; Dumontet C; Delannoy V; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux V; Bay JO; Monconduit M; Harousseau JL; Duguet C; Duhamel A; Facon T
Hematol J; 2002; 3(4):185-92. PubMed ID: 12189564
[TBL] [Abstract][Full Text] [Related]
24. Thalidomide as initial therapy for early-stage myeloma.
Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE
Leukemia; 2003 Apr; 17(4):775-9. PubMed ID: 12682636
[TBL] [Abstract][Full Text] [Related]
25. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors.
Anagnostopoulos A; Gika D; Hamilos G; Zervas K; Zomas A; Pouli A; Zorzou M; Kastritis E; Anagnostopoulos N; Tassidou A; Anagnostou D; Dimopoulos MA
Leuk Lymphoma; 2004 Nov; 45(11):2275-9. PubMed ID: 15512817
[TBL] [Abstract][Full Text] [Related]
26. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
[TBL] [Abstract][Full Text] [Related]
27. Thalidomide for previously untreated indolent or smoldering multiple myeloma.
Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE
Leukemia; 2001 Aug; 15(8):1274-6. PubMed ID: 11480571
[TBL] [Abstract][Full Text] [Related]
28. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
29. Thalidomide in the management of multiple myeloma.
Barlogie B; Tricot G; Anaissie E
Semin Oncol; 2001 Dec; 28(6):577-82. PubMed ID: 11740812
[TBL] [Abstract][Full Text] [Related]
30. Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome.
Sridhar S; Dutta TK; Basu D
J Indian Med Assoc; 2011 Dec; 109(12):880-2, 887-8. PubMed ID: 23469567
[TBL] [Abstract][Full Text] [Related]
31. Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.
Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A
Int J Hematol; 2004 May; 79(4):364-8. PubMed ID: 15218967
[TBL] [Abstract][Full Text] [Related]
32. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
[TBL] [Abstract][Full Text] [Related]
33. [The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients].
Qi PJ; Wang YF; Xu Y; Li YN; Zou DH; Zhao YZ; Xiao ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):226-9. PubMed ID: 18843974
[TBL] [Abstract][Full Text] [Related]
34. [Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma].
Kyrcz-Krzemień S; Helbig G; Stella-Hołowiecka B; Hołowiecki J
Wiad Lek; 2003; 56(5-6):227-32. PubMed ID: 14526479
[TBL] [Abstract][Full Text] [Related]
35. Thalidomide in patients with advanced multiple myeloma.
Yakoub-Agha I; Moreau P; Leyvraz S; Berthou C; Payen C; Dumontet C; Grosbois B; Beris P; Duguet C; Attal M; Harousseau JL; Facon T;
Hematol J; 2000; 1(3):186-9. PubMed ID: 11920188
[TBL] [Abstract][Full Text] [Related]
36. Thalidomide-induced severe neutropenia during treatment of multiple myeloma.
Hattori Y; Kakimoto T; Okamoto S; Sato N; Ikeda Y
Int J Hematol; 2004 Apr; 79(3):283-8. PubMed ID: 15168599
[TBL] [Abstract][Full Text] [Related]
37. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.
Rajpal R; Dowling P; Meiller J; Clarke C; Murphy WG; O'Connor R; Kell M; Mitsiades C; Richardson P; Anderson KC; Clynes M; O'Gorman P
Proteomics; 2011 Apr; 11(8):1391-402. PubMed ID: 21365752
[TBL] [Abstract][Full Text] [Related]
38. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
[TBL] [Abstract][Full Text] [Related]
39. Predicting durable remissions following thalidomide therapy for relapsed myeloma.
Quach H; Mileshkin L; Seymour JF; Milner A; Ritchie D; Harrison S; Westerman D; Prince HM
Leuk Lymphoma; 2009 Feb; 50(2):223-9. PubMed ID: 19194832
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
